Clinical trials have proved that Apatinib is effective for patients with chemotherapy-refractory gastric cancer, advanced non-small-cell lung cancer expressing wild-type epidermal growth factor receptor, breast cancer, and hepatocellular carcinoma.[29] Recently, Apatinib has been reported to show excellent effects on advanced sarcoma,[30] ovarian cancer[31] and thyroid cancer.[32] Despite the significant effects on various solid tumors, treatments with Apatinib or other anti-angiogenesis drugs on IMT have never been reported previously. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.